Article
“FDA-approved carbonic anhydrase inhibitors reduce Amyloid β pathology and improve…
medRxiv · 2022 · Canepa, E.; Parodi-Rullan, R.; Vazquez-Torres, R.; Gamallo-Lana, B.; Guzman-Hernandez, R.; Lemon, N. L.; Angiulli, F.; Debure, L.; Ilies, M.; Ostergaard, L.; Wisniewski, T.; Gutierrez-Jimenez, E.; Mar, A.; Fossati, S.
Key facts
| Title | “FDA-approved carbonic anhydrase inhibitors reduce Amyloid β pathology and improve cognition, by ameliorating cerebrovascular health and glial fitness” |
|---|---|
| First author | Canepa, E.; Parodi-Rullan, R.; Vazquez-Torres, R.; Gamallo-Lana, B.; Guzman-Hernandez, R.; Lemon, N. L.; Angiulli, F.; Debure, L.; Ilies, M.; Ostergaard, L.; Wisniewski, T.; Gutierrez-Jimenez, E.; Mar, A.; Fossati, S. |
| Journal | medRxiv |
| Published | Oct 19, 2022 |
| DOI | 10.1101/2022.07.19.500681 |
| Devices mentioned | BK110039, DEN000008, K022086, K083082, K102433, K103302, K112826 |
| Product codes mentioned | DPW, GEX, MUD, JCI, KIT, NDS, NJT, OOI, PCA |
At a glance
- 1–9 FDA submissions mentioned
- 1–9 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1